Use of procalcitonin in clinical oncology: A literature review

Andrea Sbrana, Martina Torchio, Giuditta Comolli, Andrea Antonuzzo, Marco Danova

Research output: Contribution to journalReview articlepeer-review


The use of procalcitonin (PCT) as an early marker of infectious episodes in cancer patients is still controversial. We performed a MEDLINE search of peer-reviewed articles published between January 1990 and December 2015, and finally we analysed 15 articles. PCT seems to have a good diagnostic value of infectious episodes in cancer patients and its accuracy seems greater if we consider major events, such as bloodstream infections and sepsis. Serial evaluations of this protein seem to be more accurate in the diagnostic phase and useful to predict outcome and response to antibacterial treatment. On the other hand, some issues have yet to be solved, such as the use of a validated method of determination, the definition of a standard cut-off, and the heterogeneity among different settings of patients (e.g. early versus advanced-stage cancer, or haematological versus solid tumours). However, it is credible to think that PCT use in eveiyday clinical practice, preferably in combination with other clinical or laboratory tests, might be of help in finding and detecting early infectious complications in cancer patients.

Original languageEnglish
Pages (from-to)174-180
Number of pages7
JournalNew Microbiologica
Issue number3
Publication statusPublished - Apr 1 2016


  • Biomarkers of infection
  • Cancer patients
  • Chemotherapy-induced neutropenia
  • Febrile neutropenia
  • Infections
  • Procalcitonin

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)


Dive into the research topics of 'Use of procalcitonin in clinical oncology: A literature review'. Together they form a unique fingerprint.

Cite this